BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
Patent valid through March 2034, with up to five years’ patent term extension
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
BL-8040 was safe and well tolerated, and all transplanted recipients were successfully engrafted
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
x30-50 patients in additional arm will be investigated under the collaboration. Results from combination of BL-8040 and KEYTRUDA® (pembrolizumab) in COMBAT/KEYNOTE-202 study will be reported in H2 2018 as planned.
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of motixafortide (BL-8040), a novel immunotherapy compound, combined with any PD-1 inhibitor, for the treatment of [...]
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
Data from first lead-in patient cohort prompts Data Monitoring Committee to recommend early continuation to randomized placebo-controlled part 2 of trial.
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
Transaction increases BioLineRx’s stake by 20%, to 80%, ahead of numerous potential value-creating milestones. Top-line results from ongoing Phase 2a pancreatic cancer study in combination with KEYTRUDA® expected this quarter.
BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that hematopoietic stem cells (HSCs) mobilized by BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF) were successfully engrafted in all 11 patients participating in the Part 1, lead-in period of the GENESIS trial, a double-blind, placebo-controlled Phase [...]
BioLineRx Presents Preclinical Data From Triple Combination of BL-8040
BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment. BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further elucidating the mechanism of action of BL-8040 in combination with [...]
Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE
BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer. Combination of BL-8040, KEYTRUDA® and chemotherapy demonstrates a 32% overall response rate and a 77% disease control rate out of 22 currently evaluable patients. Median duration of clinical benefit for all 17 patients with disease [...]